Infection Risk Associated With High-Efficacy Disease-Modifying Therapies for MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Pharmacology and Therapeutics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study
Clin Pharmacol Ther 2024 Nov 15;[EPub Ahead of Print], J Li, GJ Hutton, TJ Varisco, Y Lin, EJ Essien, RR AparasuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.